The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ﾙ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
RTS,S malaria vaccine reached more than 650 000 children in Ghana, Kenya and Malawi through pilot programme
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
Moderna announced new COVID-19 vaccine supply agreement with Israel for 2022
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
Johnson & Johnson COVID-19 vaccine roll-out resumed in Europe following EMA review
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
CureVac Swiss initiated rolling submission process for mRNA-based COVID-19 vaccine candidate with Swissmedic
On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacﾒs mRNA-based COVID-19…
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
Biotechnology | COVID-19 | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyﾒs COVID-19…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
Anixa Biosciences and OntoChem entered next stage of development for Covid-19 therapeutic
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
Positive phase 1/2 results reported for Valneva’s inactivated COVID-19 vaccine candidate using CpG 1018ﾙ adjuvant
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
COVID-19 variant vaccine trial began at KPWHRI
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
FDA revised Moderna COVID-19 vaccine EUA to increase the number of vaccine doses available
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…